IL193715A - Methods for predicting cardiac toxicity from tyrosine kinase inhibitor therapy - Google Patents
Methods for predicting cardiac toxicity from tyrosine kinase inhibitor therapyInfo
- Publication number
- IL193715A IL193715A IL193715A IL19371508A IL193715A IL 193715 A IL193715 A IL 193715A IL 193715 A IL193715 A IL 193715A IL 19371508 A IL19371508 A IL 19371508A IL 193715 A IL193715 A IL 193715A
- Authority
- IL
- Israel
- Prior art keywords
- fatty acid
- cells
- acid oxidation
- tyrosine kinase
- kinase inhibitor
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 49
- 238000011282 treatment Methods 0.000 title claims description 35
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title claims description 32
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title claims description 30
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 title claims description 19
- 206010048610 Cardiotoxicity Diseases 0.000 title claims description 15
- 231100000259 cardiotoxicity Toxicity 0.000 title claims description 15
- 230000007681 cardiovascular toxicity Effects 0.000 title claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 45
- 229930195729 fatty acid Natural products 0.000 claims description 45
- 239000000194 fatty acid Substances 0.000 claims description 45
- 150000004665 fatty acids Chemical class 0.000 claims description 44
- 150000002632 lipids Chemical class 0.000 claims description 40
- 238000007254 oxidation reaction Methods 0.000 claims description 40
- 230000003647 oxidation Effects 0.000 claims description 37
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 claims description 31
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 229940022353 herceptin Drugs 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 230000009467 reduction Effects 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 230000037353 metabolic pathway Effects 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 238000002493 microarray Methods 0.000 claims description 3
- 238000002600 positron emission tomography Methods 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims 4
- 238000010521 absorption reaction Methods 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 67
- 229940043355 kinase inhibitor Drugs 0.000 description 26
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 26
- DYYZXRCFCVDSKD-UHFFFAOYSA-N N6,N6-dimethyl-N4-[1-(phenylmethyl)-5-indazolyl]pyrido[3,4-d]pyrimidine-4,6-diamine Chemical compound N1=CN=C2C=NC(N(C)C)=CC2=C1NC(C=C1C=N2)=CC=C1N2CC1=CC=CC=C1 DYYZXRCFCVDSKD-UHFFFAOYSA-N 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 21
- 101000851700 Homo sapiens Steroid hormone receptor ERR1 Proteins 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 102100036832 Steroid hormone receptor ERR1 Human genes 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 210000002216 heart Anatomy 0.000 description 16
- 210000004413 cardiac myocyte Anatomy 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 13
- 230000000747 cardiac effect Effects 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 230000004913 activation Effects 0.000 description 11
- 230000002503 metabolic effect Effects 0.000 description 11
- 101710192017 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 10
- 102100024590 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 10
- 239000013543 active substance Substances 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 230000002438 mitochondrial effect Effects 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 239000012190 activator Substances 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 230000002588 toxic effect Effects 0.000 description 8
- 102100031855 Estrogen-related receptor gamma Human genes 0.000 description 7
- 102000017946 PGC-1 Human genes 0.000 description 7
- 108700038399 PGC-1 Proteins 0.000 description 7
- 108091008557 estrogen-related receptor gamma Proteins 0.000 description 7
- 108020004067 estrogen-related receptors Proteins 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 6
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 6
- 108010018763 Biotin carboxylase Proteins 0.000 description 6
- 108700012920 TNF Proteins 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000004129 fatty acid metabolism Effects 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 230000002407 ATP formation Effects 0.000 description 5
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 5
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 5
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 description 4
- 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000037149 energy metabolism Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 239000003761 preservation solution Substances 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102100029103 3-ketoacyl-CoA thiolase Human genes 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 208000031229 Cardiomyopathies Diseases 0.000 description 3
- 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 description 3
- 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004958 brain cell Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 230000007946 glucose deprivation Effects 0.000 description 3
- 230000004190 glucose uptake Effects 0.000 description 3
- 210000002064 heart cell Anatomy 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 229960004891 lapatinib Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 230000004783 oxidative metabolism Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- MPLLLQUZNJSVTK-UHFFFAOYSA-N 5-[3-[4-[2-(4-fluorophenyl)ethoxy]phenyl]propyl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1CCCC(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 MPLLLQUZNJSVTK-UHFFFAOYSA-N 0.000 description 2
- 108700038202 AMP-Activated Protein Kinase Kinases Proteins 0.000 description 2
- 108010003902 Acetyl-CoA C-acyltransferase Proteins 0.000 description 2
- 101100064707 Caenorhabditis elegans eef-2 gene Proteins 0.000 description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 2
- 101150073133 Cpt1a gene Proteins 0.000 description 2
- 102100030497 Cytochrome c Human genes 0.000 description 2
- 108010075031 Cytochromes c Proteins 0.000 description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 2
- -1 ERRJ3 Proteins 0.000 description 2
- 101710088791 Elongation factor 2 Proteins 0.000 description 2
- 206010049119 Emotional distress Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 101150014691 PPARA gene Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 101001083555 Sus scrofa Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003081 coactivator Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000006571 energy metabolism pathway Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 238000012606 in vitro cell culture Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 230000008437 mitochondrial biogenesis Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 229940094060 tykerb Drugs 0.000 description 2
- 229940035936 ubiquinone Drugs 0.000 description 2
- 102100035905 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 Human genes 0.000 description 1
- 108700032300 2,4-Dienoyl-CoA Reductase Deficiency Proteins 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- 208000009270 3-hydroxyacyl-CoA dehydrogenase deficiency Diseases 0.000 description 1
- FVZXYJDGVYLMDB-UHFFFAOYSA-N 3-pyridin-2-ylpropan-1-ol Chemical compound OCCCC1=CC=CC=N1 FVZXYJDGVYLMDB-UHFFFAOYSA-N 0.000 description 1
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 description 1
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 description 1
- 102000002281 Adenylate kinase Human genes 0.000 description 1
- 108020000543 Adenylate kinase Proteins 0.000 description 1
- 101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 description 1
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010068197 Butyryl-CoA Dehydrogenase Proteins 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 101100214824 Caenorhabditis elegans abhd-5.2 gene Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 1
- 108700017419 Carnitine-Acylcarnitine Translocase Deficiency Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102100022206 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial Human genes 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102000012737 Electron-Transferring Flavoproteins Human genes 0.000 description 1
- 108010079426 Electron-Transferring Flavoproteins Proteins 0.000 description 1
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 102000011026 Fatty Acid Binding Protein 3 Human genes 0.000 description 1
- 108010062715 Fatty Acid Binding Protein 3 Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000929840 Homo sapiens 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 Proteins 0.000 description 1
- 101000841262 Homo sapiens 3-ketoacyl-CoA thiolase Proteins 0.000 description 1
- 101000900394 Homo sapiens Cytochrome c oxidase subunit 4 isoform 1, mitochondrial Proteins 0.000 description 1
- 101001083553 Homo sapiens Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 102100030358 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 102100023379 NF-kappa-B-repressing factor Human genes 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 102000011244 Nuclear receptor coactivator Human genes 0.000 description 1
- 108050001461 Nuclear receptor coactivator Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 208000020547 Peroxisomal disease Diseases 0.000 description 1
- 102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 description 1
- 206010034764 Peutz-Jeghers syndrome Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000932075 Priacanthus hamrur Species 0.000 description 1
- 208000028269 Progressive encephalopathy with leukodystrophy due to DECR deficiency Diseases 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102000009105 Short Chain Dehydrogenase-Reductases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000012130 acyl-CoA dehydrogenase deficiency Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000457 cardiotoxic Toxicity 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 208000005071 carnitine-acylcarnitine translocase deficiency Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000020931 dietary conditions Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940127263 dual kinase inhibitor Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 1
- LTYOQGRJFJAKNA-VFLPNFFSSA-N malonyl-coa Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-VFLPNFFSSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 108090000629 orphan nuclear receptors Proteins 0.000 description 1
- 102000004164 orphan nuclear receptors Human genes 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000028503 regulation of lipid metabolic process Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- DEUWDIBQYKIQOA-ACRIIGJESA-N sodium;(2r)-2-amino-4-[4-[(z)-c-[[(3s)-1-[(r)-carboxy-(4-hydroxyphenyl)methyl]-2-oxoazetidin-3-yl]carbamoyl]-n-hydroxycarbonimidoyl]phenoxy]butanoic acid Chemical compound [Na+].C1=CC(OCC[C@@H](N)C(O)=O)=CC=C1C(=N\O)\C(=O)N[C@@H]1C(=O)N([C@@H](C(O)=O)C=2C=CC(O)=CC=2)C1 DEUWDIBQYKIQOA-ACRIIGJESA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000155 toxicity by organ Toxicity 0.000 description 1
- 230000007675 toxicity by organ Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 201000011296 tyrosinemia Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77709606P | 2006-02-27 | 2006-02-27 | |
| US82123006P | 2006-08-02 | 2006-08-02 | |
| US82737206P | 2006-09-28 | 2006-09-28 | |
| US82834506P | 2006-10-05 | 2006-10-05 | |
| US86773606P | 2006-11-29 | 2006-11-29 | |
| PCT/US2007/062871 WO2007101191A2 (en) | 2006-02-27 | 2007-02-27 | Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL193715A0 IL193715A0 (en) | 2009-05-04 |
| IL193715A true IL193715A (en) | 2014-06-30 |
Family
ID=38459790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL193715A IL193715A (en) | 2006-02-27 | 2008-08-26 | Methods for predicting cardiac toxicity from tyrosine kinase inhibitor therapy |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8709738B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1996939B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5539653B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101390625B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN101438155B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007220094B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2643846A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2475162T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL193715A (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ594178A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007101191A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010036910A1 (en) * | 2008-09-26 | 2010-04-01 | Yoshikazu Ohta | Heart protection by administering an amp-activated protein kinase activator |
| WO2015027171A1 (en) * | 2013-08-23 | 2015-02-26 | Quintiles Transnational Corporation | Methods for predicting toxicity in response to treatment with a drug by assessing activation of the sterol regulatory binding protein (srebp) pathway |
| WO2015148832A1 (en) | 2014-03-27 | 2015-10-01 | Salk Institute For Biological Studies | Compositions and methods for treating type 1 and type 2 diabetes and related disorders |
| CA2977520A1 (en) * | 2015-02-27 | 2016-09-01 | Salk Institute For Biological Studies | Reprogramming progenitor compositions and methods of use therefore |
| WO2017205511A1 (en) | 2016-05-25 | 2017-11-30 | Salk Institute For Biological Studies | Compositions and methods for organoid generation and disease modeling |
| JP7032723B2 (ja) * | 2017-07-21 | 2022-03-09 | 公立大学法人福島県立医科大学 | 薬剤の心毒性評価方法及びそのための試薬又はキット |
| WO2019084395A1 (en) | 2017-10-27 | 2019-05-02 | University Of Virginia Patent Foundation | COMPOUNDS AND METHODS FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION |
| TWI711458B (zh) * | 2019-07-08 | 2020-12-01 | 大江生醫股份有限公司 | 植物發酵物及其製備方法與用於胃臟保健的用途 |
| KR102493664B1 (ko) | 2020-01-29 | 2023-02-01 | 한국화학연구원 | 심장 독성 예측 모델링 시스템 및 모델링 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9618420D0 (en) * | 1996-09-04 | 1996-10-16 | Scotia Holdings Plc | Fatty acid treatment |
| DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
| US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| DE60233743D1 (de) * | 2001-09-24 | 2009-10-29 | Lipomics Technologies Inc | Verfahren zur verwendung von quantitativen lipidmetabolondaten |
| SG152922A1 (en) | 2002-11-04 | 2009-06-29 | Univ California | Deuterated glucose or fat tolerance tests for high-throughput measurement of the metabolism of sugars or fatty acids in the body |
| DE602004015626D1 (de) * | 2003-08-28 | 2008-09-18 | Ipsogen | Bei brustkrebs |
-
2007
- 2007-02-27 EP EP07757542.1A patent/EP1996939B1/en not_active Not-in-force
- 2007-02-27 WO PCT/US2007/062871 patent/WO2007101191A2/en not_active Ceased
- 2007-02-27 US US12/280,893 patent/US8709738B2/en not_active Expired - Fee Related
- 2007-02-27 JP JP2008556587A patent/JP5539653B2/ja not_active Expired - Fee Related
- 2007-02-27 NZ NZ594178A patent/NZ594178A/xx not_active IP Right Cessation
- 2007-02-27 CA CA002643846A patent/CA2643846A1/en not_active Abandoned
- 2007-02-27 ES ES07757542.1T patent/ES2475162T3/es active Active
- 2007-02-27 CN CN2007800136974A patent/CN101438155B/zh not_active Expired - Fee Related
- 2007-02-27 AU AU2007220094A patent/AU2007220094B2/en not_active Ceased
- 2007-02-27 CN CN2013101368247A patent/CN103217520A/zh active Pending
- 2007-02-27 KR KR1020087023650A patent/KR101390625B1/ko not_active Expired - Fee Related
- 2007-02-27 NZ NZ571465A patent/NZ571465A/en not_active IP Right Cessation
-
2008
- 2008-08-26 IL IL193715A patent/IL193715A/en not_active IP Right Cessation
-
2012
- 2012-12-26 JP JP2012282502A patent/JP2013063090A/ja active Pending
-
2013
- 2013-04-05 US US13/857,591 patent/US20130288285A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8709738B2 (en) | 2014-04-29 |
| IL193715A0 (en) | 2009-05-04 |
| EP1996939A2 (en) | 2008-12-03 |
| EP1996939B1 (en) | 2014-03-26 |
| US20090186910A1 (en) | 2009-07-23 |
| CN101438155B (zh) | 2013-04-24 |
| JP2013063090A (ja) | 2013-04-11 |
| CN103217520A (zh) | 2013-07-24 |
| CN101438155A (zh) | 2009-05-20 |
| ES2475162T3 (es) | 2014-07-10 |
| KR101390625B1 (ko) | 2014-04-29 |
| NZ571465A (en) | 2011-09-30 |
| AU2007220094A1 (en) | 2007-09-07 |
| US20130288285A1 (en) | 2013-10-31 |
| AU2007220094B2 (en) | 2013-12-05 |
| CA2643846A1 (en) | 2007-09-07 |
| WO2007101191A3 (en) | 2007-12-13 |
| WO2007101191A2 (en) | 2007-09-07 |
| JP2009533017A (ja) | 2009-09-17 |
| EP1996939A4 (en) | 2009-07-15 |
| KR20090008194A (ko) | 2009-01-21 |
| NZ594178A (en) | 2013-02-22 |
| JP5539653B2 (ja) | 2014-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008016730A2 (en) | Compositions and methods for reducing cellular fat | |
| Ma et al. | BCAA–BCKA axis regulates WAT browning through acetylation of PRDM16 | |
| Zhenyukh et al. | High concentration of branched-chain amino acids promotes oxidative stress, inflammation and migration of human peripheral blood mononuclear cells via mTORC1 activation | |
| IL193715A (en) | Methods for predicting cardiac toxicity from tyrosine kinase inhibitor therapy | |
| Zhang et al. | Sulforaphane prevents the development of cardiomyopathy in type 2 diabetic mice probably by reversing oxidative stress-induced inhibition of LKB1/AMPK pathway | |
| Hussien et al. | Mitochondrial and plasma membrane lactate transporter and lactate dehydrogenase isoform expression in breast cancer cell lines | |
| Wang et al. | Obesity accelerates ovarian follicle development and follicle loss in rats | |
| Leandro et al. | Omentin: A novel therapeutic approach for the treatment of endothelial dysfunction in type 2 diabetes | |
| Hayot et al. | Myostatin up-regulation is associated with the skeletal muscle response to hypoxic stimuli | |
| Chen et al. | Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation | |
| Wilson et al. | Pyruvate induces mitochondrial biogenesis by a PGC-1 α-independent mechanism | |
| Kwon et al. | Effect of low glutamine/glucose on hypoxia-induced elevation of hypoxia-inducible factor-1α in human pancreatic cancer MiaPaCa-2 and human prostatic cancer DU-145 cells | |
| Barjaste et al. | Concomitant aerobic-and hypertrophy-related skeletal muscle cell signaling following blood flow-restricted walking | |
| Wang et al. | AMPK is involved in mediation of erythropoietin influence on metabolic activity and reactive oxygen species production in white adipocytes | |
| Yusoff et al. | Bach1 plays an important role in angiogenesis through regulation of oxidative stress | |
| Xiao et al. | Inhibitory effect of Sirtuin6 (SIRT6) on osteogenic differentiation of bone marrow mesenchymal stem cells | |
| Kalezic et al. | Level of NO/nitrite and 3-nitrotyrosine in seminal plasma of infertile men: Correlation with sperm number, motility and morphology | |
| Kihara et al. | Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells | |
| Bhat et al. | Pharmacological inhibition of serine palmitoyl transferase and sphingosine kinase-1/-2 inhibits merkel cell carcinoma cell proliferation | |
| Yan et al. | WY14643 improves left ventricular myocardial mitochondrial and systolic functions in obese rats under chronic persistent hypoxia via the PPARα pathway | |
| EP3361250B1 (en) | Midodrine for inducing exercise-like effects | |
| Huang et al. | Peroxisomal gene and protein expression increase in response to a high-lipid challenge in human skeletal muscle | |
| Li et al. | High-fat feeding in cardiomyocyte-restricted PPARδ knockout mice leads to cardiac overexpression of lipid metabolic genes but fails to rescue cardiac phenotypes | |
| Li et al. | High fat-induced the upregulation of LOX-1 in RF/6A cells under high glucose condition | |
| AU2017346267A1 (en) | Pharmaceutical composition for preventing or treating diabetes and/or hyperlipidemia comprising midorine or pharmaceutically acceptable salt thereof as active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |